Skip to content
Open access

Ai-THERO Study: a population-based analysis of patients at high or very high risk of atherosclerotic cardiovascular disease and low-density lipoprotein cholesterol (LDL-C) levels in Cantabria, Spain

Oct 2026 · European Heart Journal · Vol 47 · 0 citations

TL;DR

This is the first study to describe the characteristics of patients at HR/VHR according to the ESC/EAS guidelines across an entire region in Spain and highlights the need for more intensive lipid-lowering therapy and optimized clinical management in HR/VHR patients.

Abstract

Atherosclerotic Cardiovascular Disease (ASCVD) remains a major public health challenge in developed countries, including Spain. However, large scale population-based studies describing the clinical burden of patients at high (HR) or very high (VHR) cardiovascular risk and their attainment of recommended LDL-C goals are scarce. To describe the population at HR or VHR of ASCVD in Cantabria, Spain and to assess their characteristics and achievement of LDL-C goals. Observational, retrospective, population-based study analyzing electronic health records from an integrated hospital-primary care database of 493,808 individuals in the Cantabrian region (Spain) during an 8-year follow-up (January 2016 to January 2024). Natural Language Processing technology (NLP) was applied to extract structured and unstructured data into a unified database mapped to the Observational Medical Outcomes Partnership (OMOP) Common Data Model. Identification of HR or VHR patients for ASCVD and their LDL-C goal attainment were assessed according to the 2019 ESC/EAS guidelines criteria and to the most recent LDL-C available during the study period. A total of 97,101 subjects (19.7% of the overall adult population) were identified as HR/VHR patients [mean (SD) age 71.2 years (14.9), 49.6% female, 49.9% with diabetes and 79.7% with hypertension] (Table 1). Of these, 35,021 (36.1%) were classified as HR and 62,080 (63.9%) as VHR patients. Among VHR individuals, 41,282 (66.5%) had documented ASCVD. Prevalence estimates for the overall adult population of Cantabria are shown in Figure 1. Among VHR patients with ASCVD, 18,806 (45.6%) had coronary heart disease, 19,569 (47.4%) cerebrovascular disease and 11,075 (26.8%) peripheral artery disease. Overall, only 17,386 HR and VHR patients (17.9%) had their LDL-C at goal with lower attainment found in VHR patients without ASCVD. The mean (SD) absolute reduction needed to reach recommended LDL-C goals was 42.5 (34.1) mg/dl [1.2 mmol/L], corresponding to a mean percentage reduction of 35.8% (18.0), similar across all risk subgroups (Table 1). To our knowledge, this is the first study to describe the characteristics of patients at HR/VHR according to the ESC/EAS guidelines across an entire region in Spain. Based on these results, 19.7% of the adult population of Cantabria was identified as HR/VHR for ASCVD. LDL-C goal attainment was suboptimal, and a substantial additional LDL-C reduction would be needed to reach the currently recommended targets. These results highlight the need for more intensive lipid-lowering therapy and optimized clinical management in HR/VHR patients.

Read PDF

Similar papers

Open access Oct 2026

The independent association of mortality with LDL-C management, and number and types of atherosclerotic cardiovascular disease events: a large nationwide real-world cohort study

In a large nationwide cohort, recurrent ASCVD events and multi-bed disease were associated with markedly higher mortality compared to patients experiencing single ASCVD events, highlighting the need for earlier, more intensive, and sustained prevention- particularly aggressive LDL-C lowering and comprehensive risk fact...

M. H. Moshe Hoshen, V. B. Vishal Bali, S. Moser et al. · 0 citations
Open access Oct 2026

Lipid-lowering therapy use and LDL-C goal achievement in patients with hypercholesterolaemia or mixed dyslipidaemia in Hong Kong: findings from a retrospective database study

Despite strong guideline recommendations for intensive lipid-lowering therapy (LLT), real-world attainment of LDL-C targets remains suboptimal, particularly in the Asian population. Data describing treatment patterns and LDL-C goal achievement across cardiovascular (CV) risk strata in Hong Kong are limited....

B. Yan, M. Kim, S. Tsukiyama et al. · 0 citations
Open access Sep 2026

GUIDELINE-DIRECTED LIPID GOAL ATTAINMENT IN PATIENTS WITH DIABETES AT HIGH AND VERY HIGH CARDIOVASCULAR RISK: REAL-WORLD EVIDENCE OF A PROFOUND TREATMENT GAP

Objective: To evaluate lipid-lowering therapy patterns and the attainment of guideline-directed low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C) goals among high and very high-risk patients with diabetes mellitus in a real-world clinical setting.Material and Methods:...

Tolga Aydin · 0 citations
Open access Oct 2026

Individual and combined prognostic value of LDL-C, Lp(a), and hsCRP for cardiovascular and cerebrovascular events in post-PCI patients: evidence from two large contemporary cohorts

Substantial residual cardiovascular risk persists in patients with coronary artery disease (CAD) despite contemporary secondary prevention. While combined assessment of low-density lipoprotein cholesterol (LDL-C), lipoprotein(a) [Lp(a)], and high-sensitivity C-reactive protein (hsCRP) has demonstrated prognostic...

K. Zhang, K. Yan, M. Liu et al. · 0 citations
Open access Oct 2026

Prognostic value of high-sensitivity C-reactive protein versus low-density lipoprotein cholesterol for recurrent atherosclerotic cardiovascular disease events using US real-world data

Measuring CV inflammation (hsCRP ≥2 mg/L) could be a potentially valuable means of CV risk prediction in individuals with ASCVD, and hsCRP consistently predicted recurrent CV events and mortality in this US real-world study.

F. Kahles, R. Howden, B. Kalyanam et al. · 0 citations
Open access Oct 2026

Association of Lipoprotein(a) with cardiovascular and all-cause mortality in China: a cohort study based on cardiorenal improvementNT-II

The threshold effect of Lp(a) is sought to elucidate to identify possible intervention targets and strategies for this high-risk population of individuals aged ≥18 years with confirmed coronary artery disease (CAD).

G. Yuan, X. Lu, Z. Yuan et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.